GeparSepto — Nab-Paclitaxel Versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer

Phase 3 · 2016 · Breast Cancer

Design

Randomized weekly nab-paclitaxel vs solvent-based paclitaxel, each followed by epirubicin-cyclophosphamide, as neoadjuvant therapy.

Population

Early breast cancer (with HER2-targeted therapy for HER2-positive disease).

Primary Endpoint

pathologic complete response (pCR)

Key Result

Nab-paclitaxel raised pCR (38% vs 29%), with the largest benefit in triple-negative disease and improved survival on follow-up.

Guideline Impact

Influenced taxane selection in neoadjuvant breast cancer regimens